SCHEMBL17700565

SCHEMBL17700565

CC(I)c1cc(Br)ccc1OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 5/20 0.58
ALDH1A1 P00352 3/20 0.56
RAB9A P51151 1/20 0.56
SLC6A4 P31645 1/20 0.48
HTR7 P34969 1/20 0.47
HTR6 P50406 1/20 0.47
USP28 Q96RU2 1/20 0.47
USP25 Q9UHP3 1/20 0.47
MAOB P27338 1/20 0.46
LMNA P02545 3/20 0.46
HTT P42858 2/20 0.46
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LRRK2 Q5S007 1/20 0.44
PTGER1 P34995 1/20 0.43
PTPN1 P18031 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3915066 0.88 CCR5 (0.60) CCR5ALDH1A1RAB9ASLC6A4HTR7
SCHEMBL8161790 0.87 CCR5 (0.59) CCR5ALDH1A1RAB9ASLC6A4HTR7
SCHEMBL8166488 0.85 CCR5 (0.58) CCR5ALDH1A1RAB9ASLC6A4HTR7
SCHEMBL11890513 0.84 CCR5 (0.56) CCR5ALDH1A1RAB9ASLC6A4HTR7
SCHEMBL31065358 0.82 CCR5 (0.53) CCR5ALDH1A1RAB9ASLC6A4USP28
SCHEMBL80676 0.82 CCR5 (0.53) CCR5ALDH1A1RAB9ASLC6A4USP28
SCHEMBL724632 0.81 CCR5 (0.53) CCR5ALDH1A1RAB9ASLC6A4HTR7
SCHEMBL15148414 0.81 CCR5 (0.53) CCR5ALDH1A1RAB9ASLC6A4HTR7
SCHEMBL23599912 0.81 USP28 (0.54) CCR5ALDH1A1RAB9ASLC6A4USP28
SCHEMBL16294377 0.80 PTGER1 (0.54) CCR5ALDH1A1RAB9AUSP28USP25

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9657006-B2 Macrocyclic factor VIIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-05-23 US disclosed
US-20160115159-A1 MACROCYCLIC FACTOR VIIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160115159-A1 MACROCYCLIC FACTOR VIIA INHIBITORS F7, F12, F5 CCR5 3177/4885ALDH1A1 2603/4885RAB9A 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.